SEC Comment Letter for GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416) (GALT) — Apr 15, 2008

GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416)
Date: April 15, 2008 · CIK: 0001133416 · Accession: 0000000000-08-019509

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 15, 2008

Author

Jeffrey P. Riedler

Form

UPLOAD

Company

GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416)

Letter

Mail Stop 6010 April 15, 2008 David Platt, Ph.D. Chief Executive Officer and Chairman of the Board Pro-Pharmaceuticals, Inc. 7 Wells Avenue Newton, Massachusetts 02459 Re: Pro-Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 3, 2008 File No. 1-31791

Dear Dr. Platt: We have completed our review of your preliminary proxy statement on Schedule 14A and have no further comments at this time.

Sincerely,
J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r

Show Raw Text

Mail Stop 6010                                                                                                   April 15, 2008   David Platt, Ph.D. Chief Executive Officer and Chairman of the Board Pro-Pharmaceuticals, Inc. 7 Wells Avenue Newton, Massachusetts 02459
 Re: Pro-Pharmaceuticals, Inc.
  Preliminary Proxy Statement on Schedule 14A   Filed April 3, 2008   File No. 1-31791

Dear Dr. Platt:   We have completed our review of  your preliminary proxy statement on
Schedule 14A and have no further comments at this time.

Sincerely,

          J e f f r e y  P .  R i e d l e r          A s s i s t a n t  D i r e c t o r

cc: Jonathan C. Guest, Esq.
Greenberg Traurig LLP  One International Place  Boston, Massachusetts 02110

SecProbe.io